<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04141462</url>
  </required_header>
  <id_info>
    <org_study_id>EX²TRICAN</org_study_id>
    <nct_id>NCT04141462</nct_id>
  </id_info>
  <brief_title>EXOME Analysis Position in the Strategy of Genetic Predisposition Factors Identification in Early-onset Cancer</brief_title>
  <acronym>EX²TRICAN</acronym>
  <official_title>EXOME Analysis Position in the Strategy of Genetic Predisposition Factors Identification in Early-onset Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Georges Francois Leclerc</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Georges Francois Leclerc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      5 to 10% of cancers are due to the presence of a constitutional genetic alteration. It can be
      inherited from parents (family form) or by accident, in the first moments of life after
      fertilization (sporadic form). In both cases, this genetic alteration is constitutional and
      transmissible to descendants. It is hereditary. When an hereditary early form is suspected,
      several well-known genes generally involved in genetic predispositions to cancer are found by
      a technique called &quot; gene panel &quot;. However, this analysis does not always identify the
      genetic predisposing factors for cancer. New techniques called &quot;high-throughput exome
      sequencing (SHD-E)&quot;, allow more than the analysis of the the gene panel. These analysis allow
      to identify alterations in other genes that could contribute to the development of cancer.
      The objective of the Ex²trican study is to show, from patients with early cancer (sporadic or
      familial form), that this approach to exome sequencing can be effective to identify new
      genetic risk of cancer, when the first panel analysis of genes is negative.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective of this study is to evaluate the interest of the SHD-E approaches after a
      negative result of the analysis called &quot; gene panel &quot; tested in routine in order to identify
      a genetic factor of predisposition to the cancer.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 2, 2019</start_date>
  <completion_date type="Anticipated">October 10, 2024</completion_date>
  <primary_completion_date type="Actual">October 10, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>genetic mutations</measure>
    <time_frame>inclusion</time_frame>
    <description>SHD-E analysis</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">613</enrollment>
  <condition>Cancer</condition>
  <condition>Genetic Predisposition</condition>
  <arm_group>
    <arm_group_label>Patients with a a constitutional genetic alteration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>one genetic consultation and one blood test</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>blood sample</intervention_name>
    <description>blood test</description>
    <arm_group_label>Patients with a a constitutional genetic alteration</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Index case:

          1. Major or minor patient

          2. Histological or cytological evidence of malignant tumor diagnosis

          3. Patient with cancer before age 40 (or before age 30 for breast cancer).

          4. Absence of anomaly found on the oncogenetic panel tested in the predisposition
             concerned

          5. Patient affiliated to a social security scheme

          6. Signature of Informed Consent EXTRICAN

          7. Availability of a tumor sample if needed secondary functional studies

          8. Availability of both parents when the trio approach will be necessary in the
             population 1 (or validation of the indication in CPR in case of non-availability of
             both parents)

          9. Availability of affected relatives in population 2 (or validation of the indication in
             SPC in case of non-availability of the related person)

        Related:

          1. Major or minor patient

          2. Histological or cytological evidence of the diagnosis of malignant tumor if

          3. Patient affiliated to a social security scheme

          4. Signing informed consent EXTRICAN

        Exclusion Criteria:

        Index and related case:

          1. Refusal of the patient participation

          2. Psychiatric illness and / or condition of the patient compromising the understanding
             of the information or the realization of the study

          3. Patient under guardianship, curatorship or safeguard of justice

          4. Pregnant woman
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Laurence FAIVRE, PH</last_name>
    <phone>03 80 29 53 13</phone>
    <email>laurence.faivre@cgfl.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emilie REDERSTORFF</last_name>
    <phone>03 45 34 81 16</phone>
    <email>erederstorff@cgfl.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHRU Jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marie-Agnès COLLONGE-RAME</last_name>
      <phone>03 81 21 81 87</phone>
      <email>macollongerame@chu-besancon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Georges-François Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurence FAIVRE, PH</last_name>
      <phone>03 80 29 53 13</phone>
      <email>laurence.faivre@cgfl.fr</email>
    </contact>
    <contact_backup>
      <last_name>Emilie REDERSTORFF, PhD</last_name>
      <phone>03 45 34 81 16</phone>
      <email>erederstorff@cgfl.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Laurence FAIVRE, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>François GHIRINGHELLI, PU PH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurence FAIVRE</last_name>
      <phone>03 80 29 53 13</phone>
      <email>laurence.faivre@cgfl.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Reims</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Monique MOZELLE</last_name>
      <phone>03 26 78 90 03</phone>
      <email>mmozelle@chu-reims.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Polyclinique de Courlancy</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Frederique CARRE-PIGEON</last_name>
      <phone>03 26 78 90 03</phone>
      <email>Fcarre-pigeon@groupe-courlancy.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH de Troyes</name>
      <address>
        <city>Troyes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Monique MOZELLE</last_name>
      <phone>03 25 49 49 14</phone>
      <email>Monique.mozelle@ch-troyes.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 23, 2019</study_first_submitted>
  <study_first_submitted_qc>October 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 28, 2019</study_first_posted>
  <last_update_submitted>October 24, 2019</last_update_submitted>
  <last_update_submitted_qc>October 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>genetic mutations</keyword>
  <keyword>early sporadic or familial cancer</keyword>
  <keyword>gene panel</keyword>
  <keyword>exome analysis</keyword>
  <keyword>high-throughput exome sequencing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease Susceptibility</mesh_term>
    <mesh_term>Genetic Predisposition to Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

